|
楼主 |
发表于 2014-8-22 14:06:31
|
显示全部楼层
来自: 中国广东广州
本帖最后由 419808415 于 2014-8-30 17:40 编辑
[quote]419808415 发表于 2014-8-22 10:22
但是检测了EGFR、ALK、ROS都是阴性,没有合适的靶向药吃,VEGFR类盲打化疗有效,不过已六疗程了,有缓慢 ...
已知的肺腺癌致癌驱动(根源)基因 和 靶药
ALK - Crizotinib克药, LDK378, AP26113, CH5424802
BRAF - share targeted therapy with melanoma drug, Vemurafenib
EGFR - 特罗凯, 易瑞莎, 2992阿法替尼, WZ4002,凡德它尼
HER2 - share targeted therapy with breast cancer, herceptin,2992,PF299804
KRAS - no targeted therapy available currently(暂时没药)
MET - Crizotinib克药, and prostate cancer drug cabozantinib XL-184
PIK3CA - BLM120(有YL药了)
RET - share targeted therapy with GIST and kidney cancer drug, Sunitinib(索坦); leukemia drug ponatinib; thyroid cancer drug Vandetanib(凡德); and prostate cancer drug Cabozantinib (XL184)
ROS - Crizotinib克药, AP26113
T790M - WZ4002,CO-1686,AZ9291
目前免疫治疗药物有如下公司在开发,供参考:
Nivolumab:Bristol Myers Squibb百时美施贵宝的PD-1单抗
BMS-936559:Bristol Myers Squibb百时美施贵宝的PD-L1单抗
Pidilizumab:CureTech的PD-1单抗
MPDL3280A:Roche罗氏的PD-L1单抗
MK-3475:Merck 默克的PD-1单抗 |
|